Files
Download Full Text (501 KB)
Contents
- Novel Agents for Castrate-Resistant Prostate Cancer Include Potent Androgen Blockers and Immunotherapies: Despite progress in screening and therapy, prostate cancer continues to be a leading cause of cancer death among men worldwide
- New Targeted Therapy Offers Hope in Relapsed Hodgkin and Anaplastic large-Cell Lymphoma: The U.S. Food and Drug Administration (FDA) has approved the first new drug for Hodgkin Lymphoma since 1977
- HOUSE CALL: Colorectal Cancer Screening: Risk factors determine who should be screened and how often
- IN BRIEF: Everolimus may Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer Patients
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Publication Date
9-1-2011
Publisher
The University of Texas MD Anderson Cancer Center
City
Houston, Texas
Keywords
Corn, Paul; Sharma, Padmanee; Younes, Anas; Fanale, Michelle; Oki, Yasuhiro; Morrow, Phuong Khanh; Esteva, Francisco J.; Prostatic Neoplasms, Castration-Resistant; Androgen Antagonists; Immunotherapy; Hormones -- therapeutic use; Clinical Trials as Topic; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Colorectal Neoplasms; Early Detection of Cancer; Colonoscopy; Sigmoidoscopy; Barium Enema; Breast Neoplasms.
Disciplines
History of Science, Technology, and Medicine | Oncology
Recommended Citation
Munch, Joe and Tutt, Bryan, "Oncology, Volume 56, Number 09, September 2011" (2011). OncoLog MD Anderson's Report to Physicians (All issues). 218.
https://openworks.mdanderson.org/oncolog/218
Conditions Governing Access
Open
